AOCNP EXAM COMPREHENSIVE
PRACTICE TEST QUESTIONS &
VERIFIED ANSWERS (A+ GUARANTEE)
1. Which of the following describes the primary mechanism of action for immune checkpoint
inhibitors such as Nivolumab?
A. Inhibiting the VEGF pathway to prevent angiogenesis
B. Targeting the BCR-ABL fusion protein in leukemic cells
C. Directly inducing apoptosis in tumor cells via DNA intercalation
D. Binding to PD-1 receptors on T-cells to block inhibitory signals
Answer: D
Conceptual Explanation: Nivolumab is a monoclonal antibody that binds to the PD-1
receptor on T-cells, preventing interaction with PD-L1/PD-L2 on tumor cells, thereby
restoring T-cell anti-tumor activity.
2. A patient with Multiple Myeloma presents with hypercalcemia, renal insufficiency, and
new-onset back pain. Which diagnostic finding is most consistent with the CRAB criteria?
A. Serum calcium < 8.5 mg/dL
B. Clonal bone marrow plasma cells < 5%
C. Hemoglobin > 14 g/dL
,D. Monoclonal protein peak on SPEP
Answer: D
Conceptual Explanation: The CRAB criteria for Multiple Myeloma include Calcium
elevation, Renal insufficiency, Anemia, and Bone lesions. A monoclonal (M) protein peak on
serum protein electrophoresis (SPEP) is a hallmark of the disease.
3. During the administration of Paclitaxel, the patient develops dyspnea, hypotension, and a
generalized rash. What is the immediate priority action?
A. Decrease the infusion rate by 50%
B. Administer intramuscular epinephrine
C. Stop the infusion and assess the airway
D. Administer IV diphenhydramine and continue the infusion
Answer: C
Conceptual Explanation: Paclitaxel is associated with hypersensitivity reactions. The
infusion must be stopped immediately if a severe reaction occurs to prevent anaphylaxis,
followed by airway assessment.
4. A patient receiving High-Dose Methotrexate must be monitored for which specific toxicity,
necessitating leucovorin rescue?
A. Hemorrhagic cystitis
B. Myelosuppression and mucosal toxicity
, C. Ototoxicity
D. Cardiomyopathy
Answer: B
Conceptual Explanation: Leucovorin provides a source of reduced folate to ‘rescue’
normal cells from the lethal effects of Methotrexate, primarily targeting myelosuppression
and mucositis.
5. What is the gold standard for managing Breakthrough Pain (BTP) in a patient with cancer
who is already on a stable dose of long-acting opioids?
A. Increasing the dose of the long-acting opioid
B. Switching to a different opioid class (opioid rotation)
C. Administering a short-acting opioid at 10-20% of the total daily basal dose
D. Adding a non-steroidal anti-inflammatory drug (NSAID)
Answer: C
Conceptual Explanation: Breakthrough pain is typically managed with a supplemental
dose of a short-acting opioid, usually calculated as 10% to 20% of the total 24-hour dose of
the long-acting opioid.
6. In a patient with suspected Spinal Cord Compression (SCC), which initial intervention is
most critical after confirming the diagnosis via MRI?
A. Initiate prophylactic anticoagulation
PRACTICE TEST QUESTIONS &
VERIFIED ANSWERS (A+ GUARANTEE)
1. Which of the following describes the primary mechanism of action for immune checkpoint
inhibitors such as Nivolumab?
A. Inhibiting the VEGF pathway to prevent angiogenesis
B. Targeting the BCR-ABL fusion protein in leukemic cells
C. Directly inducing apoptosis in tumor cells via DNA intercalation
D. Binding to PD-1 receptors on T-cells to block inhibitory signals
Answer: D
Conceptual Explanation: Nivolumab is a monoclonal antibody that binds to the PD-1
receptor on T-cells, preventing interaction with PD-L1/PD-L2 on tumor cells, thereby
restoring T-cell anti-tumor activity.
2. A patient with Multiple Myeloma presents with hypercalcemia, renal insufficiency, and
new-onset back pain. Which diagnostic finding is most consistent with the CRAB criteria?
A. Serum calcium < 8.5 mg/dL
B. Clonal bone marrow plasma cells < 5%
C. Hemoglobin > 14 g/dL
,D. Monoclonal protein peak on SPEP
Answer: D
Conceptual Explanation: The CRAB criteria for Multiple Myeloma include Calcium
elevation, Renal insufficiency, Anemia, and Bone lesions. A monoclonal (M) protein peak on
serum protein electrophoresis (SPEP) is a hallmark of the disease.
3. During the administration of Paclitaxel, the patient develops dyspnea, hypotension, and a
generalized rash. What is the immediate priority action?
A. Decrease the infusion rate by 50%
B. Administer intramuscular epinephrine
C. Stop the infusion and assess the airway
D. Administer IV diphenhydramine and continue the infusion
Answer: C
Conceptual Explanation: Paclitaxel is associated with hypersensitivity reactions. The
infusion must be stopped immediately if a severe reaction occurs to prevent anaphylaxis,
followed by airway assessment.
4. A patient receiving High-Dose Methotrexate must be monitored for which specific toxicity,
necessitating leucovorin rescue?
A. Hemorrhagic cystitis
B. Myelosuppression and mucosal toxicity
, C. Ototoxicity
D. Cardiomyopathy
Answer: B
Conceptual Explanation: Leucovorin provides a source of reduced folate to ‘rescue’
normal cells from the lethal effects of Methotrexate, primarily targeting myelosuppression
and mucositis.
5. What is the gold standard for managing Breakthrough Pain (BTP) in a patient with cancer
who is already on a stable dose of long-acting opioids?
A. Increasing the dose of the long-acting opioid
B. Switching to a different opioid class (opioid rotation)
C. Administering a short-acting opioid at 10-20% of the total daily basal dose
D. Adding a non-steroidal anti-inflammatory drug (NSAID)
Answer: C
Conceptual Explanation: Breakthrough pain is typically managed with a supplemental
dose of a short-acting opioid, usually calculated as 10% to 20% of the total 24-hour dose of
the long-acting opioid.
6. In a patient with suspected Spinal Cord Compression (SCC), which initial intervention is
most critical after confirming the diagnosis via MRI?
A. Initiate prophylactic anticoagulation
